Jiangsu Hengrui Medicine Co., Ltd.

This study tests an experimental drug called SHR0302Base in 155 adults with stable nonsegmental vitiligo, a condition where white patches appear on the skin. The goal is to see if the drug can safely restore at least 50% of color to the face and neck over several months. Particip…

This study compares a new medicine called SHR-3167 to insulin glargine in people with type 2 diabetes who are not yet on insulin. Participants take either drug alongside their current metformin or SGLT2 inhibitor pills. The main goal is to see which treatment better lowers blood …

This study tests a new medicine called SHR-3167 against a standard insulin (insulin degludec) in people with type 2 diabetes who already use basal insulin. The goal is to see which one controls blood sugar better and is safer. About 173 adults aged 18-65 will take part, and the m…

This early-phase study tests a new drug, HRS-6209, in 56 adults with advanced solid tumors who have exhausted standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. It is not a cure but aims to control the disease.

This study tests whether adding an experimental drug (HR070803) to standard chemotherapy and targeted therapy can help people with advanced colorectal cancer live longer without their cancer growing. About 669 adults with stage IV colorectal cancer that cannot be removed by surge…

This study tests whether adding two drugs (camrelizumab and rivoceranib) to a standard procedure called TACE can help people with incurable liver cancer live longer without the disease getting worse. About 423 participants will receive either the combination or TACE alone. The go…

This phase 3 trial tests whether a combination of two drugs (camrelizumab and rivoceranib) can prevent liver cancer from returning in patients who have a high risk of recurrence after surgery or ablation. About 687 participants will either receive the drug combination or be close…

This study tests whether a combination of two drugs (camrelizumab and famitinib) works better than standard chemotherapy for women with cervical cancer that has returned or spread. About 443 women aged 18-75 who have not had prior treatment for advanced disease will take part. Th…

This study tests a new drug called SHR-A1811, given alone or with another drug (pertuzumab), against the current standard treatment for HER2-positive breast cancer that has come back or spread. About 868 women aged 18 to 75 with advanced HER2-positive breast cancer will take part…

This study tests a new drug called HRS-4642 combined with other cancer medicines in people with advanced solid tumors that have a specific genetic change (KRAS G12D). The goal is to check safety, find the best dose, and see if the combination shrinks tumors. About 47 adults aged …

This early-phase study tests a new drug, HRS-4642, in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The main goal is to find a safe dose and check for side effects. About 102 adults with this mutation who have few other options will take …

This early-stage study aims to understand how a single dose of the investigational drug HRS-9190 is absorbed, broken down, and removed from the body. Six healthy men aged 18-45 will receive the drug and provide blood, urine, and stool samples over time. The results will help rese…